<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857425</url>
  </required_header>
  <id_info>
    <org_study_id>KY20192009-F-1</org_study_id>
    <nct_id>NCT03857425</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets</brief_title>
  <official_title>Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating efficacy Clostridum Butyricum Capsule and Bacillus Coagulans
      Tablets in H. pylori eradication. It is hypothesized that Clostridum Butyricum Capsule ,
      Bacillus Coagulans Tablets monotherapy or Clostridum Butyricum Capsule plus Bacillus
      Coagulans may have some positive effect on H. pylori eradication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include three phases: screening, treatment and follow-up. Screening: during
      this phase subjects eligibility will be evaluated after informed consent signature. Endoscopy
      and Urea Breath test will be performed in addition to the baseline routine evaluations.

      Treatment: Subjects are randomly assigned to treatment and will be treated for 8weeks.

      Follow-up: includes one visits. Eradication of H. Pylori will be confirmed through urea
      breath test(UBT).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">September 15, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>helicobacter pylori eradication H.pylori eradication</measure>
    <time_frame>8 weeks</time_frame>
    <description>Rate of H.pylori eradication Assessed by urea breath testï¼Œrapid urease test or helicobacter pylori stool antigen test after the end of treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Gastritis</condition>
  <condition>H Pylori Infection</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Clostridum Butyricum Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacillus Coagulans Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clostridum Butyricum Capsule</intervention_name>
    <description>Clostridum Butyricum Capsule 3*420mg,twice daily for 8 weeks</description>
    <arm_group_label>Clostridum Butyricum Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacillus Coagulans Tablets</intervention_name>
    <description>Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks</description>
    <arm_group_label>Bacillus Coagulans Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets</intervention_name>
    <description>Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks</description>
    <arm_group_label>Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18~70,both gender.

          2. Patients with upper gastrointestinal symptoms and with documented H.pylori infection.

          3. Patients are willing to receive eradication treatment.

          4. Women are eligible if they are not pregnant or nursing, and if they are of
             childbearing potential they are required to use medically acceptable contraception for
             the duration of the study and 30 days thereafter.

        Exclusion Criteria:

          1. Patients are excluded if they have previously used antibiotics to eradicate adequately
             recorded infection with H. pylori.

          2. Contraindications to study drugs.

          3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.

          4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI)
             within 2 weeks before the [13C] urea breath test), antibiotics or bismuth complexes
             (more than 3 times /1 month before screening).

          5. Pregnant or lactating women.

          6. Patients were diagnosed with gastroduodenal ulcer and MALT lymphoma.

          7. Underwent upper gastrointestinal Surgery.

          8. Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of
             dysphagia.

          9. Evidence of bleeding or iron efficiency anemia.

         10. A history of malignancy.

         11. Drug or alcohol abuse history in the past 1 year.

         12. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,
             anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less
             than 100 mg/d).

         13. Enrolled in other clinical trials in the past 3 months.

         14. Patients who has psychological problem or poor compliance.

         15. Refuse to sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hosipital of Digestive Disease</name>
      <address>
        <city>Xi`an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Yongquan Shi</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Gastritis</keyword>
  <keyword>H Pylori Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

